Eficacia y seguridad de una estrategia basal plus en pacientes con diabetes mellitus tipo 2 en la práctica clínica especializada. El estudio Basal Plus en España

Wild, 2004, Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030, Diabetes Care, 27, 1047, 10.2337/diacare.27.5.1047 Soriguer, 2012, Prevención de la diabetes mellitus tipo 2, Med Clin (Barc), 139, 640, 10.1016/j.medcli.2012.03.015 Oliva, 2004, Direct healthcare costs of diabetic patients in Spain, Diabetes Care, 27, 2616, 10.2337/diacare.27.11.2616 Menéndez Torre, 2010, Diabetología para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2, Av Diabetol, 26, 331, 10.1016/S1134-3230(10)65006-5 Inzucchi, 2012, Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetes Care, 35, 1364, 10.2337/dc12-0413 1995, BMJ, 310, 83, 10.1136/bmj.310.6972.83 Turner, 1999, UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49), JAMA, 281, 2005, 10.1001/jama.281.21.2005 Jabbour, 2008, Primary care physicians and insulin initiation: Multiple barriers, lack of knowledge or both, Int J Clin Pract, 62, 845, 10.1111/j.1742-1241.2008.01757.x Linn, 2008, Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes, J Clin Endocrinol Metab, 93, 3839, 10.1210/jc.2007-2871 Holman, 2007, Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes, N Engl J Med, 357, 1716, 10.1056/NEJMoa075392 Holman, 2009, Three-year efficacy of complex insulin regimens in type 2 diabetes, N Engl J Med, 361, 1736, 10.1056/NEJMoa0905479 Lankisch, 2008, Introducing a simplified approach to insulin therapy in type 2 diabetes: A comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs, Diabetes Obes Metab, 10, 1178 Riddle, 2003, The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients, Diabetes Care, 26, 3080, 10.2337/diacare.26.11.3080 Riddle, 2011, Comparison of 3 intensified insulin regimens added to oral therapy for type 2 diabetes: Twice-daily aspart premixed vs glargine plus 1 prandial glulisine or stepwise addition of glulisine to glargine, Diabetes, 60, A0409 Marchante, 2010, Implementación de la estrategia basal plus en la práctica clínica, Av Diabetol, 26, 339, 10.1016/S1134-3230(10)65007-7 Owens, 2011, Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: A 6-month ‘proof-of-concept’ study, Diabetes Obes Metab, 13, 1020, 10.1111/j.1463-1326.2011.01459.x Davidson, 2009, Effects of 1, 2 o 3 prandial injections of insulin glulisine on glycemic control in type 2 diabetes patients on insulin glargine and oral drugs, Diabetes, 58, A132